ETON Stock - Eton Pharmaceuticals, Inc.
Unlock GoAI Insights for ETON
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $39.01M | $31.64M | $21.25M | $21.83M | $39,000 |
| Gross Profit | $23.41M | $21.06M | $14.32M | $19.21M | $-247,000 |
| Gross Margin | 60.0% | 66.6% | 67.4% | 88.0% | -633.3% |
| Operating Income | $-2,597,000 | $-1,192,000 | $-8,260,000 | $-1,495,000 | $-27,111,000 |
| Net Income | $-3,823,000 | $-936,000 | $-9,021,000 | $-1,955,000 | $-27,970,000 |
| Net Margin | -9.8% | -3.0% | -42.4% | -9.0% | -71717.9% |
| EPS | $-0.15 | $-0.04 | $-0.36 | $-0.08 | $-1.33 |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Visit WebsiteEarnings History & Surprises
ETONEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 17, 2026 | $0.12 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.16 | $-0.07 | -143.8% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.01 | $-0.10 | -900.0% | ✗ MISS |
Q2 2025 | May 13, 2025 | $0.09 | $0.07 | -22.2% | ✗ MISS |
Q1 2025 | Mar 18, 2025 | $-0.02 | $-0.02 | 0.0% | = MET |
Q4 2024 | Nov 12, 2024 | $0.00 | $0.02 | +400.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.07 | $-0.12 | -71.4% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.07 | $-0.03 | +57.1% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-0.04 | $-0.09 | -125.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.10 | $-0.02 | +80.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.09 | $0.15 | +266.7% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.14 | $-0.10 | +28.6% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $0.01 | $0.04 | +300.0% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.01 | $-0.06 | -300.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.08 | $-0.21 | -162.5% | ✗ MISS |
Q1 2022 | Mar 16, 2022 | $0.19 | $0.04 | -78.9% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.14 | $-0.24 | -71.4% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.14 | $-0.08 | +42.9% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $0.19 | $0.19 | 0.0% | = MET |
Latest News
Frequently Asked Questions about ETON
What is ETON's current stock price?
What is the analyst price target for ETON?
What sector is Eton Pharmaceuticals, Inc. in?
What is ETON's market cap?
Does ETON pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ETON for comparison